Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2009 1
2010 2
2011 2
2012 3
2013 3
2014 3
2015 1
2016 2
2017 4
2020 1
2022 3
2023 1
2024 1

Text availability

Article attribute

Article type

Publication date

Search Results

20 results

Results by year

Filters applied: . Clear all
Page 1
FibroScan-AST (FAST) score for the non-invasive identification of patients with non-alcoholic steatohepatitis with significant activity and fibrosis: a prospective derivation and global validation study.
Newsome PN, Sasso M, Deeks JJ, Paredes A, Boursier J, Chan WK, Yilmaz Y, Czernichow S, Zheng MH, Wong VW, Allison M, Tsochatzis E, Anstee QM, Sheridan DA, Eddowes PJ, Guha IN, Cobbold JF, Paradis V, Bedossa P, Miette V, Fournier-Poizat C, Sandrin L, Harrison SA. Newsome PN, et al. Among authors: sheridan da. Lancet Gastroenterol Hepatol. 2020 Apr;5(4):362-373. doi: 10.1016/S2468-1253(19)30383-8. Epub 2020 Feb 3. Lancet Gastroenterol Hepatol. 2020. PMID: 32027858 Free PMC article. Clinical Trial.
A phase II, randomized, open-label, 52-week study of seladelpar in patients with primary biliary cholangitis.
Bowlus CL, Galambos MR, Aspinall RJ, Hirschfield GM, Jones DEJ, Dörffel Y, Gordon SC, Harrison SA, Kremer AE, Mayo MJ, Thuluvath PJ, Levy C, Swain MG, Neff GW, Sheridan DA, Stanca CM, Berg CP, Goel A, Shiffman ML, Vierling JM, Boudes P, Steinberg A, Choi YJ, McWherter CA. Bowlus CL, et al. Among authors: sheridan da. J Hepatol. 2022 Aug;77(2):353-364. doi: 10.1016/j.jhep.2022.02.033. Epub 2022 Mar 30. J Hepatol. 2022. PMID: 35367282 Free article. Clinical Trial.
Lipids and HCV.
Bassendine MF, Sheridan DA, Bridge SH, Felmlee DJ, Neely RD. Bassendine MF, et al. Among authors: sheridan da. Semin Immunopathol. 2013 Jan;35(1):87-100. doi: 10.1007/s00281-012-0356-2. Epub 2012 Oct 31. Semin Immunopathol. 2013. PMID: 23111699 Review.
Hepatitis C virus and atherosclerosis: A legacy after virologic cure?
Bassendine MF, Nielsen SU, Bridge SH, Felmlee DJ, Sheridan DA, Packard CJ, Neely RD. Bassendine MF, et al. Among authors: sheridan da. Clin Res Hepatol Gastroenterol. 2017 Feb;41(1):25-30. doi: 10.1016/j.clinre.2016.09.008. Epub 2016 Nov 11. Clin Res Hepatol Gastroenterol. 2017. PMID: 27840032 Review.
HCV and the hepatic lipid pathway as a potential treatment target.
Bassendine MF, Sheridan DA, Felmlee DJ, Bridge SH, Toms GL, Neely RD. Bassendine MF, et al. Among authors: sheridan da. J Hepatol. 2011 Dec;55(6):1428-40. doi: 10.1016/j.jhep.2011.06.004. Epub 2011 Jun 28. J Hepatol. 2011. PMID: 21718665 Free article. Review.
Open-label, clinical trial extension: Two-year safety and efficacy results of seladelpar in patients with primary biliary cholangitis.
Mayo MJ, Vierling JM, Bowlus CL, Levy C, Hirschfield GM, Neff GW, Galambos MR, Gordon SC, Borg BB, Harrison SA, Thuluvath PJ, Goel A, Shiffman ML, Swain MG, Jones DEJ, Trivedi P, Kremer AE, Aspinall RJ, Sheridan DA, Dörffel Y, Yang K, Choi YJ, McWherter CA. Mayo MJ, et al. Among authors: sheridan da. Aliment Pharmacol Ther. 2024 Jan;59(2):186-200. doi: 10.1111/apt.17755. Epub 2023 Oct 30. Aliment Pharmacol Ther. 2024. PMID: 37904314
20 results